114 results about "Atherosclerotic disease" patented technology

A laser catheter is disclosed wherein optical fibers carrying laser light are mounted in a catheter for insertion into an artery to provide controlled delivery of a laser beam for percutaneous intravascular laser treatment of atherosclerotic disease. A transparent protective shield is provided at the distal end of the catheter for mechanically diplacing intravascular blood and protecting the fibers from the intravascular contents, as well as protecting the patient in the event of failure of the fiber optics. Multiple optical fibers allow the selection of tissue that is to be removed. A computer controlled system automatically aligns fibers with the laser and controls exposure time. Spectroscopic diagnostics determine what tissue is to be removed.

Techniques and devices for treating atherosclerotic disease use controlled cryogenic cooling, often in combination with angioplasty and/or stenting. A combination cryogenic/angioplasty catheter may cool the diseased blood vessel before, during, and/or after dilation. Controlled cooling of the vessel wall reduces actual/observed hyperplasia as compared to conventional uncooled angioplasty. Similar reductions in restenosis may be provided for other primary treatments of the blood vessel, including directional arthrectomy, rotational arthrectomy, laser angioplasty, stenting, and the like. Cooling of vessel wall tissues will often be performed through plaque, and the cooling process will preferably take the thermodynamic effects of the plaque into account.

Devices for excluding aneurysms and treating atherosclerotic disease, for intra-aneurysmal occlusion; and devices for preventing distal emboli. The devices are generally pliable and collapsible thin film devices which can be delivered via a microcatheter into the desired location where they are deployed and undergo either a shape memory phase transformation or in situ polymerization to assume the stable configuration of a permanent endoluminal prosthesis. Prior to being caused to assume their final shape, the devices remain soft, collapsible and pliable to ensure atraumatic delivery through the vascular system. Upon reaching the endoluminal defect in the vessel, the device is extruded from the microcatheter. Devices are also provided for retrieving clots.

Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.

The invention provides a novel human Mab Fab, cloned by phage display, and its use in diagnostic and therapeutic methods. In particular the invention provides a method for analyzing the OxLDL components of atherosclerotic plaques in vivo and a means to determine their relative pathology. As the method is based on a human Fab rather than a mouse Mab, the progress or regression of the disease may be monitored over time. The antibody may also be used for the analysis of surgical or serum samples ex vivo for the presence of OxLDL. The antibody may also be used to target therapeutic agents to the site of atherosclerotic plaques or may have use as a therapeutic agent itself.

This invention provides cholesterol absorption inhibitors of Formula I:

and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.

This invention provides cholesterol absorption inhibitors of Formula I:

and the pharmaceutically acceptable salts thereof, wherein R¹² is an alkyl, alkeny or alkynyl group mono- or poly-substituted with —OH, —COOH or a combination of—OH and —COOH, and R⁹ contains an alkyl, alkeny or alkynyl group substituted with a heterocyclic ring, amino or sulfonyl. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.

This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment also are described.

The invention discloses a solid lipid nanoparticle containing andrographolide, a preparation method and application thereof. The solid lipid nanoparticle is composed of 1-20% andrographolide, 20-60% lipid material and 30-60% emulsifier. The preparation of described solid lipid nanoparticle comprises: adding andrographolide, lipid material and emulsifier in the organic solvent, heating makes to dissolve completely; The organic solvent is evaporated, is cooled with ice bath to form solid; Take Tween- Dissolve 80 in water to obtain the water phase; mix the obtained solid with the obtained water phase, and stir at high speed to disperse the solid uniformly to obtain colostrum; perform high-pressure homogenization treatment at room temperature, and then rapidly cool on an ice bath. The solid lipid nanoparticles containing andrographolide can be used in the form of a single form or a combination with a pharmaceutically acceptable drug carrier for the prevention and treatment of hyperlipidemia and/or atherosclerosis In the preparation of pharmaceutical preparations.

Methods, devices, and kits, for assessing luminal lesions rely on intraluminal detection of labeled annexin. Annexin coupled to a detectable marker is introduced to a body lumen, either into the lumen itself or systemically in patient circulation, and localizes at a lesion. The detector is introduced into the body lumen and the localize distribution of the detectable marker is detected in situ. The information is useful for a number of purposes including the identification of unstable plaque in patients suffering from atherosclerotic disease.

The invention discloses a serum or RLP density in the plasma testing method, which is characterized by the following: adopting immune combined direct method or immune sediment separating method; providing effective estimation and reference accordance for atherosclerotic disease, coronary disease and relative metabolic disease of atherosclerotic disease.

The invention relates to a device for culturing endothelial cells of myocardial bridge-mural coronary artery, which is characterized in that a pair of myocardial bridge press block and simulated coronary artery is arranged in an airtight cavity, a motor drives the myocardial bridge press block to press the simulated coronary artery, and the outer part of the airtight cavity is connected with a proportional pressure-regulating constant-current stabilizer consisting of an air compressor, an air reservoir, a proportional pressure valve and a tank pressure sensor; after a periodic pulsatile flow produced by a heart pump passes through an energy accumulator, the liquid is divided into two branches, i.e. one branch of the fluid flows through a division to flow into a liquid storage tank and a constant temperature device after loading, and the other branch of the fluid flows through the airtight cavity to flow into the liquid storage tank and the constant temperature device after loading. Inthe invention, the endothelial cells are cultured in the pulsatile flow, so that the physiological environment of the coronary artery periodically oppressed by the myocardial bridge can be simulated,and the stress on the endothelial cells in the coronary artery can be independently adjusted relatively, therefore, the method of the invention provides an experimental means for studying the relation between the form and function of the endothelial cell and the proximal coronary atherosclerotic diseases in the presence of the myocardial bridge.

This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.

Polynucleotide sequences are provided that correspond to genes that are differentially expressed in atherosclerotic disease conditions. Methods for using these sequences to detect gene expression and/or for transcriptional profiling in mammals are also provided. The polynucleotide sequences of the invention may be used, for example, to diagnose atherosclerotic disease, to monitor extent of progression or efficacy of treatment or to assess prognosis of atherosclerotic disease, and/or to identify compounds effective to treat an atherosclerotic disease condition.